Dren Bio IncLicence dealSanofi to acquire Dren Bio’s bispecific myeloid cell engager DR-201French Sanofi SA announced that it will acquire Dren Bio Inc’s bispecific myeloid cell engager DR-0201 for upfront US$600m and US$1.3bn in milestones. The deal is expected to close in Q2/2025. more ➔
Brainomix Ltd.FinancingBrainomix Ltd. completes £14m Series C financingUniversity of Oxford spinout Brainomix Ltd has closed a £14m Series C round to advance its commercial expansion in the US. Funding will also support clinical uptake of its AI imaging technology in stroke … more ➔
EvonikEconomic growthUS President deprioritises biotechnologyThe U.S. administration of President Donald Trump has revoked Executive Order 14081, “Advancing Biotechnology and Biomanufacturing Innovation for a Sustainable, Safe, and Secure American Bioeconomy,” … more ➔
Adobe stock photos - DARIKAFinancingSofinnova Partners closes €165m Biovelocita II biotech acceleration fundSofinnova Partners has raised €165m within its biotech acceleration fund Biovelocita II that attracted investments fromBig Pharma including Amgen, Bristol Myers Squibb, and Pfizer Ventures. more ➔
Polish Ministry of Agriculture - MRiRWNGTPoland breaks opposition to EU NGT deregulationAt the third attempt, the Polish Council Presidency has broken the resistance of the member states against the deregulation of crops produced by new genomic technologies (NGT). The new draft will enter … more ➔
SpliceBioGene therapySpliceBio lauches Phase I/II study on dual-AAV-based therapy for Stargardt DiseaseSpanish SpliceBio has dosed the first patient with SB-007, the first dual AAV gene therapy in clinical development for Stargardt disease more ➔
FSA UKCell-based meatRegulatory sandbox will speed up safety assessment of cell-based foodThe UK Food Standards Agency (FSA) has selected eight companies to participate in a two-year regulatory programme set to speed up market approval and safety assessment of cell-cultivated products. more ➔
asobe stock photos - catalin ObesityRoche inks US$1.65bn obesity deal with Zealand PharmaRoche is extending its obesity pipeline signing a US$5.3bn biobucks deal with Zealand Pharma A/S, who will co-develop and co-commercialise a monotherapy of its long-acting amylin analogue petrelintide … more ➔
Adobe stock - maurice norbert ObesityNovo Nordisk’s obesity drug CagriSema disappoints againNovo Nordisk A/S’ combined GLP1-, amylin- and calcitonin receptor agonist CagriSema has failed to meet the expected 25% weight loss within 68 weeks in the second of four pivotal Phase III trials. Shares … more ➔
Roche AGSLAS/AutomationRoche unveils completely new sequencing approachRoche researchers have introduced a greatly improved long-read nanopore sequencing method that has the potential to erase the sequencing-by-synthesis approach of market leader Illumina. more ➔
Dren Bio Inc
Brainomix Ltd.
Evonik
Adobe stock photos - DARIKA
Polish Ministry of Agriculture - MRiRW
SpliceBio
FSA UK
asobe stock photos - catalin 
Adobe stock - maurice norbert 
Roche AG